Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.

Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerr, D. J., Rustin, G. J., Kaye, S. B., Selby, P., Bleehen, N. M., Harper, P., Brampton, M. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033922/
https://www.ncbi.nlm.nih.gov/pubmed/7577480
_version_ 1782136943457337344
author Kerr, D. J.
Rustin, G. J.
Kaye, S. B.
Selby, P.
Bleehen, N. M.
Harper, P.
Brampton, M. H.
author_facet Kerr, D. J.
Rustin, G. J.
Kaye, S. B.
Selby, P.
Bleehen, N. M.
Harper, P.
Brampton, M. H.
author_sort Kerr, D. J.
collection PubMed
description Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.
format Text
id pubmed-2033922
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20339222009-09-10 Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Kerr, D. J. Rustin, G. J. Kaye, S. B. Selby, P. Bleehen, N. M. Harper, P. Brampton, M. H. Br J Cancer Research Article Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer. Nature Publishing Group 1995-11 /pmc/articles/PMC2033922/ /pubmed/7577480 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Kerr, D. J.
Rustin, G. J.
Kaye, S. B.
Selby, P.
Bleehen, N. M.
Harper, P.
Brampton, M. H.
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
title Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
title_full Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
title_fullStr Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
title_full_unstemmed Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
title_short Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
title_sort phase ii trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033922/
https://www.ncbi.nlm.nih.gov/pubmed/7577480
work_keys_str_mv AT kerrdj phaseiitrialsofrhizoxininadvancedovariancolorectalandrenalcancer
AT rustingj phaseiitrialsofrhizoxininadvancedovariancolorectalandrenalcancer
AT kayesb phaseiitrialsofrhizoxininadvancedovariancolorectalandrenalcancer
AT selbyp phaseiitrialsofrhizoxininadvancedovariancolorectalandrenalcancer
AT bleehennm phaseiitrialsofrhizoxininadvancedovariancolorectalandrenalcancer
AT harperp phaseiitrialsofrhizoxininadvancedovariancolorectalandrenalcancer
AT bramptonmh phaseiitrialsofrhizoxininadvancedovariancolorectalandrenalcancer

Ejemplares similares